Saturday , 22 February 2025
0

No products in the cart.

Worldwide News Worldwide News
0

No products in the cart.

Home Health 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders
Health

3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders

September 13, 20241 Mins read55 Views
3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders

Bicara Therapeutics’ IPO raised $315 million raised for Phase 3 testing of a bifunctional antibody drug with potential to become a first-line treatment for head and neck cancers. Zenas BioPharma and MBX Biosciences also went public; all three companies upsized their IPOs.

The post 3 Biotech IPOs, $703M Raised for Clinical Trials in Cancer, Immunology & Endocrine Disorders appeared first on MedCity News.

Previous post Pan-Atlantic University Hosts Second Annual Media Roundtable On Constructive Media Engagement In Governance

Leave a comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Articles

A paper by Proudman et al. (2024) finds that doing so would...

ByFebruary 22, 2025
Health

Carlyle and SK Capital Partners are buying beleaguered gene therapy biotech Bluebird...

ByFebruary 21, 2025

This fact sheet provides an overview of the history of the Kemp-Kasten...

ByFebruary 21, 2025

Katherine Saunders is the co-founder and CMO at FlyteHealth. She was one...

ByFebruary 21, 2025

Abous us

Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Aenean commodo ligula eget dolor. Aenean massa. Cum sociis natoque penatibus et magnis dis

Subscribe Now

    Subscribe to our mailing list to receives daily updates direct to your inbox!
    © Copyright 2022 Jellywp. All rights reserved powered by Jellywp.com